KRAS and adenocarcinoma: More specifically, KRAS and TP53 variants were found co-occurring in 6 blood samples (6/41, 14.6%) with 50.0% being adenocarcinomas, while KRAS and PIK3CA in 7 samples (7/41, 17.1%) co-occurred, of which 57.1% were squamous cell carcinomas (Figure 1).